Veraxa Biotech (NASDAQ:VRXA) Director Christoph Samuel Ziegler Purchases 30,000 Shares of Company Stock

Veraxa Biotech Holding AG (NASDAQ:VRXA) Director Christoph Samuel Ziegler bought 30,000 shares of the firm’s stock in a transaction dated Tuesday, October 20th. The shares were acquired at an average cost of $1.09 per share, with a total value of $32,700.00. Following the completion of the transaction, the director owned 37,932 shares of the company’s stock, valued at $41,345.88. This represents a 378.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Veraxa Biotech Trading Up 5.0%

Shares of Veraxa Biotech stock opened at $1.06 on Thursday. Veraxa Biotech Holding AG has a 12-month low of $0.99 and a 12-month high of $27.36.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research note on Monday, August 31st.

Veraxa Biotech Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.